Drugs for specific purposes, not provided for in groups and a61p0001000000-a61p0041000000 (A61P43)

A   Human necessities(312083)
A61P43                 Drugs for specific purposes, not provided for in groups ; a61p0001000000-a61p0041000000(1106)
Composition for increasing operability and physical durability // 2642673
FIELD: food industry; pharmaceutical industry.SUBSTANCE: invention relates to the pharmaceutical and food industries and is a composition for improving working capacity and physical endurance comprising vitamin A, vitamin E and succinic acid, characterized in that it further comprises dry guarana extract and a chocolate mass, the components in the composition being in a certain ratio, in mass %.EFFECT: invention provides good taste qualities, a convenient form for reception, and also provides for a short time increase in efficiency and physical endurance by taking a complex of active substances optimally selected and in an amount sufficient to achieve maximum effect.1 cl, 3 ex, 2 tbl

Polymeric protein microparticles // 2642664
FIELD: pharmacology.SUBSTANCE: microparticles containing a core of therapeutic protein and a top layer of biocompatible and biodegradable polymer, and methods for production and application of these microparticles are proposed. The prolonged release of the therapeutic protein from the microparticles into saline is demonstrated over an extended period of time.EFFECT: group of inventions allows to expand the arsenal of available pharmaceuticals.18 cl, 3 dwg, 7 tbl, 9 ex

Therapeutic agent for diseases based on inhibiting action on microphaging migration inhibition factor // 2641301
FIELD: pharmacology.SUBSTANCE: invention relates to an inhibitor of a migration inhibition factor for macrophages containing a benzopyran derivative represented by the general formula [1] or a salt thereof, wherein R1 is a C1-6 alkyl group; one of R2 and R3 is a hydrogen atom and the other of R2 and R3 is a hydrogen atom, an amino group, an acylamino group, a carbamoyl group or an aryl group, as well as a drug against neuropathic pain, excluding the symptoms of allodynia in neuropathic pain, based on the compounds of formula I.EFFECT: increased means effeciency.9 cl, 4 tbl, 1 dwg
icroelement preparation for animals // 2640908
FIELD: agriculture.SUBSTANCE: preparation comprises 2Na- or 2K-salt of ethylenediamine-N,N1-disuccinic acid in an amount of 20.0-50.0 wt %; Na- or K-salt of an amino acid or an amino acid in an amount of 3.0-15.0 wt %; iron (III) in an amount of 0.3-3.0 wt %; magnesium (II) in an amount of 0.3-3.0 wt %; manganese (II) in an amount of 0.4-2.5 wt %; copper (II) in an amount of 0.05-0.25 wt %; zinc (II) in an amount of 0.3-2.5 wt %; cobalt (II) in an amount of 0.005-0.05 wt %; selenium (IV) in an amount of 0.01-0.03 wt %; iodine (I) in an amount of 0.03-0.08 wt %; water - the rest.EFFECT: invention provides a high efficiency of the application of the claimed preparation for the prevention and treatment of chronic intoxication with heavy metals.2 cl, 5 tbl, 4 ex

ethod for dihydroquercetin microtubes production // 2640413
FIELD: pharmacology.SUBSTANCE: invention relates to a method for preparation of a new form of bioflavonoid dihydroquercetin (DQ) in the form of microtubes, characterized by DQ mixing with urea at a ratio of 70:30 (wt %), the mixture is dissolved in ethyl alcohol in a ratio of 20:80 wt %, distilled water is added dropwise to the solution to a pH of 7, the mother liquor is maintained at a temperature of (+5)-(+35)°C for 36 hours, the product obtained is filtered off and air-dried. The formed microtubes are a polymorphic form of DQ and do not contain urea impurities. The product has a tubular structure and shows capillary properties, as well as high sorption ability comparable or exceeding the common commercial analogues, and the solubility of DQ microtubes is much higher than the solubility of the original substance.EFFECT: obtaining of tubular forms of dihydroquercetin, capable of maintaining a micro-ordered structure in the open air.4 dwg, 5 tbl
ethod for differential organ preservation treatment of cervical pregnancy and pregnancy in uterine scar after caesarean section, depending on data of integrated ultrasound and levels of human chorionic gonadotropin (versions) // 2640191
FIELD: medicine.SUBSTANCE: after emergency hospitalization, bilateral embolization of the uterine arteries (UAE) is performed, including methotrexate administration of in the amount of 50 mg endoarterially in the presence of ultrasound signs of chorion infiltration with formation of vascular malformation and HCG level increase. The gestational sac is left. 3 days after, ultrasound and HCG control is performed. With a HCG decrease in by at least 25% and no visualization of blood flow in the chorion with ultrasound and colour Doppler mapping (CDM), the patient is released for outpatient monitoring. With blood flow persistence in the chorion, UAE is repeated with a search for these vessels. If there is insufficient decrease in the blood plasma HCG, the patient receives methotrexate into the gestational sac cavity in an amount of 2-10 mg. In the absence of ultrasound signs of chorionic growth, the gestational sac is removed simultaneously under the control of ultrasound. In the absence of bleeding and normal data of the control ultrasound after 1 day, the patient is released for outpatient monitoring. In the presence of ultrasound signs of chorionic ingrowth and decreasing level of HCG, UAE without endoarterial administration of methotrexate is performed. 3 days after, ultrasound and HCG control are performed. With a HCG decrease in by at least 10% and no visualization of blood flow in the chorion with ultrasound and CDM, the patient is released for outpatient monitoring.EFFECT: maintaining the uterus integrity and its reproductive function while reducing the duration of hospitalization.4 cl, 5 ex
Oral pharmaceutical composition // 2639473
FIELD: pharmacology.SUBSTANCE: invention represents a medicinal form of a non-coated pill containing α,α,α-trifluorothymidine and hydrochloride 5-chloro-6-(2-iminopyrrolidine-1-yl)methyl-2,4(1N,3N)pyrimidinedione as active ingredients and, as such, not containing additives, including salt metals. The invention also includes a method for stabilization of an oral pharmaceutical composition containing the active ingredients described above.EFFECT: increased stability of the medicinal form.11 cl, 18 ex, 5 tbl
ethod for feeding of infants with mucoviscidosis // 2639450
FIELD: medicine.SUBSTANCE: dry milk product "Pre Nutrilak" is used, in which a portion of water needed for mixture dilution in standard concentration, is replaced with a saline solution of 0.9% sodium chloride, the amount of which depends on the air temperature in the room and the body weight of the child. At the air temperature of 20°C and child weight of up to 5 kg, 60 ml of physiological saline is required to dilute the required amount of dry mixture,10 kg - 90 ml of physiological solution, at the temperature of 25°C and child weight of up to 5 kg - 170 ml of physiological solution, at the child weight of 5-10 kg - 230 ml of physiological solution, at the temperature of 30°C and child weight of up to 5 kg - 280 ml of physiological solution, and at the child weight of 5-10 kg - 450 ml of physiological solution, with feeding frequency of is 7-10 times a day.EFFECT: method allows to provide the necessary daily dose of sodium chloride and to adapt the therapeutic diet of infants with mucoviscidosis.4 tbl, 2 ex
ethod for spleen lymphoid tissue reconstruction in laboratory animals // 2639404
FIELD: medicine.SUBSTANCE: laboratory animals (mice) receive intravenous allogeneic transplantation of multipotent stromal cells (MMSC) and hemopoietic stem cells (HSC) obtained from the laboratory animal placenta chorion 20 minutes after irradiation. At that, MMSC are administered at a dose of 6.2 million cells/kg, and HSC - at a dose of 330 thousand cells/kg.EFFECT: increased activation of spleen lymphoid tissue regeneration compared to other doses of stem cells introduction.2 tbl

ethods and compositions for huntington disease treatment // 2639277
FIELD: biotechnology.SUBSTANCE: invention refers to a "zinc fingers" protein of non-natural origin that binds to the Htt gene, which can be used in medicine. The specified "zinc fingers" protein, as well as fusion protein that includes the specified protein functionally associated with a nuclease domain, a polynucleotide, encoding the specified protein and the specified fusion protein, a host cell for obtaining of the specified protein and the specified fusion protein, a pharmaceutical composition for Htt gene expression suppression in the cell are obtained. The invention also provides a method for Htt gene expression suppression, a method for Huntington's disease treatment.EFFECT: invention effectively suppresses the Htt gene expression, which allows successful treatment of Huntington's disease.24 cl, 15 dwg, 7 tbl, 20 ex
ethod for prevention and treatment of physical development violations in children associated with complex low-level habitat pollution by lead, manganese, nickel, chromium and cadmium // 2639124
FIELD: medicine.SUBSTANCE: "Pantogam" preparation is introduced orally 15-20 minutes after eating, in an age-defined dosage rate for 21 days; "Multi-tabs Junior", 1 pill once a day for 21 days; "Reamberin" intravenously dropwise: 5 to 10 years - 200 ml once a day, 11 to 15 years - 400 ml once a day, in an amount of 5-7 injections daily or every other day for 7 days; "Eslidin" 1 capsule twice a day before meals in the morning and evening for 21 days; "Enterosgel" 1.5-2 h before or 2 hours after meals or after taking medicines, for children aged 5 to 10 years - 15 g twice a day, 11 to 15 years- 15 g 3 times a day, course lasts 7 days. Physiotherapy is also used in the form of TNF-therapy, therapeutic exercises, respiratory gymnastics and conditioning procedures. Treatment and prevention are conducted twice a year by courses of 21 days.EFFECT: increased efficiency of treatment.5 cl, 7 tbl

ethods and compositions for treating inflammation and ischemic damage // 2638807
FIELD: pharmacology.SUBSTANCE: following are proposed: method for treating a subject suffering from ischemic damage or an acute ischemic event, comprising administering cysteamine, cystamine or a salt thereof, simultaneously with or immediately after the ischemic event, in an amount effective to reduce the ischemic damage, wherein the subject does not suffer from hypercholesterolemia or diabetes of II type, where the administration of cysteamine, cystamine or a salt thereof leads to an increase in adiponectin level with low molecular weight (LMW) (versions) in subjects; a method for increasing (versions) adiponectin levels with LMW in the mentioned patient group comprising contacting the subject with an effective amount of cysteamine, cystamine or a salt thereof (versions); the use of cysteamine, cystamine or a salt thereof in the manufacture of a medicament in the above mentioned treatment of a subject suffering from the acute ischemic event and not suffering from hypercholesterolemia or diabetes of II type.EFFECT: levels of all adiponectin multimers are increased, within 1 hour after cysteamine exposure in the blood serum, LMW of adiponectin was rapidly and significantly increased, cysteamine administration 2 hours before the ischemic stroke significantly reduced the infarction area and the number of ischemic damages.28 cl, 18 dwg, 2 tbl, 3 ex
Veterinary method for noise aversion reduction // 2638804
FIELD: veterinarymedicine.SUBSTANCE: animal receives an effective amount of dexmedetomidine, medetomidine or a pharmacologically acceptable salt thereof, for example in the form of an oromucosal gel. Also, application of dexmedetomidine, medetomidine or a pharmaceutically acceptable salt thereof for the manufacture of a drug for reduction of noise aversion in animals is proposed.EFFECT: decreased noise aversion in dogs.11 cl, 1 tbl, 3 ex
ethod for directed destruction of cancer cells // 2638446
FIELD: medicine.SUBSTANCE: their preliminary visualization is performed by introduction of a complex consisting of combined photosensitizer molecules, fluorescent nanoparticles fluorescing in the infrared spectral region, and biological recognition molecules into the object under study. The complex further includes one or more plasmon nanoparticles. At that, semiconductor fluorescent nanocrystals that fluoresce in the infrared region of the spectrum are used as fluorescent nanoparticles. Irradiation of cancer cells localization is continued in the optical absorption range of fluorescent nanoparticles for detection of a fluorescent signal from fluorescent nanoparticles and subsequent induction cancer cells destruction process.EFFECT: method provides non-invasive detection and directed destruction of cancer cells localized at great depth, with increased efficiency of visualization and destruction of cancer cells.16 cl, 1 dwg, 1 ex
Sorbent based on kelp fiber // 2637436
FIELD: pharmacology.SUBSTANCE: sorbent based on kelp fiber, possessing a sorption activity in relation to the heavy metal salts and MMW liquid toxicants, is algulose, cleaned from water-soluble components, with a particle size of 0.05-0.2 mm, with a mesoporous structure, the main components of which are algal cellulose and hardly hydrolysable proteins, which is obtained by supercritical fluid extraction of air-dry kelp, under certain conditions.EFFECT: sorbent possesses high sorption capacity to salts of heavy metals and MMW toxicants of liquid media.1 dwg, 2 tbl, 3 ex

eans for intestinal fibrosis treatment // 2637372
FIELD: pharmacology.SUBSTANCE: invention refers to a carrier for a medicinal product for intestinal fibrosis treatment through medicinal product delivery to inhibit growth or activity of cells producing an extracellular matrix in the intestine, which can be used in medicine. The specified carrier contains retinoid and lipid where retinoid contributes to the drug delivery to these cells and intestinal fibrosis treatment, which is used in the pharmaceutical compositions for intestinal fibrosis treatment and regeneration of normal tissue of the intestine from the fibrous tissue, in a kit for reception of the specified pharmaceutical compositions, method for intestinal fibrosis treatment, as well as regeneration of normal tissue of the intestine from the fibrous tissue.EFFECT: invention allows highly effective delivery of the extracellular matrix product inhibitor to the cell, producing the extracellular matrix, and inhibition of the expression of molecules involved in the extracellular matrix production.15 cl, 4 dwg, 4 ex

Photosensitive chimeric protein gpcr // 2637367
FIELD: biotechnology.SUBSTANCE: invention relates to production of a photosensitive chimeric protein capable of incorporating a light signal into the signalling cascade of metabotropic glutamate receptor 6 (mGluR6), which is a natural component of the ON-bipolar cell membrane in the inner layer of the retina, which can be used in medicine. A GPCR chimeric protein is obtained comprising domains of at least two members of a protein receptor superfamily conjugated with G proteins (GPCR), a nucleic acid encoding the said protein, an expression vector comprising the said nucleic acid, as well as a transgenic cell line containing genetic information, encoding a chimeric GPCR protein.EFFECT: invention allows effective drug therapy and production of an effective drug for vision improvement, in particular, for treatment of vision loss due to degeneration of retinal photoreceptors.32 cl, 6 dwg, 1 tbl, 1 ex
Agent-prebiotic for sheep // 2636621
FIELD: veterinary medicine.SUBSTANCE: agent-prebiotic for sheep includes sodium chloride, copper sulfate, zinc sulfate, manganese sulfate, Mohr's salt - ammonium ferrous sulphate, polyethylene glycol and prebiotic inulin vegetable, with the following components: sodium chloride- 10 g, copper sulfate-70 mg, zinc sulfate-325 mg, manganese sulfate-352 mg, Mohr's salt-95 mg, polyethylene glycol-250 mg, inulin vegetable- 5.4 g. The inclusion of inulin vegetable in the composition provides stimulation of bifido-and lactobacterium, as a result of which the optimal composition of the intestinal microflora is restored.EFFECT: use ofthe agent can effectively prevent the enzootic ataxia of newborn lambs, normalize the microflora of the gastrointestinal tract.2 tbl,1 ex
Pharmaceutical or cosmetic composition for alopecia treatment // 2635627
FIELD: pharmacology.SUBSTANCE: group of inventions is a pharmaceutical or cosmetic composition for use against hair loss wherein a compound selected from compounds of the formula: (II) H2N-(CH2)3-N1(CH3)-(CH2)4-NH2, (III) H2N-(CH2)3-N1(C6H11)-(CH2)4-NH2, (IV) H2N-(CH2)3-N1(C2H5)-(CH2)4-NH2, (V) H2N-(CH2)3-N1(C3H7)-(CH2)4-NH2, (VI) H2N-(CH2)3-N1(C4H9)-(CH2)4-NH2, or a pharmaceutically acceptable salt thereof, is mixed with excipients suitable for topical application to the scalp, as well as a N1-isobutylspermidine compound or a N-(3-aminopropyl)-N1-isobutyl-1,4-butanediamine of the formula: (VI) H2N-(CH2)3-N1(C4H9)-(CH2)4-NH2. These compounds are stable with respect to air and can effectively use the invention for topical application to the scalp without conversion to oxidized by-products.EFFECT: inventions provide a more active action against alopecia in comparison with spermidine.19 cl, 9 dwg, 11 ex
ethod for cardioplegia // 2635523
FIELD: medicine.SUBSTANCE: to stop the heart and maintain it in a stopped state, a cardioplegic solution is used which is obtained from the following components: potassium chloride - 7.45 g; magnesium sulfate - 2.34 g; trometamol - 0.5 g; mannitol - 35.9 g; distilled water - up to 1000 ml, with introduction of 1 M hydrochloric acid until a pH of 7.6-8.0, which is mixed with blood from the oxygenator in a ratio of 1:1 to 1:4 and injected into the heart at a rate of 100-300 ml/min using at least 400 ml of solution; and to maintain the asystole, a cardioplegic solution is used which is obtained from the following components: potassium chloride - 2.125 g; magnesium sulfate - 2.34 g; trometamol - 0.5 g; mannitol - 58.28 g; distilled water - up to 1000 ml, with introduction of 1 M hydrochloric acid until a pH of 7.6-8.0, which is mixed with blood from the oxygenator in a ratio of 1:4 and injected into the heart at a rate of 100-150 ml/min.EFFECT: improved safety of cardioplegia using different cardioplegic solutions.3 ex

Cell content removal and recovery in organs and tissues // 2635478
FIELD: medicine.SUBSTANCE: vascular tissue of a pig, cow, sheep, dog or human, deprived of cells by perfusion, containing cell-free extracellular matrix of the said tissue is proposed. This extracellular matrix includes a vascular tree. This cell-free extracellular matrix of the said tissue retains most of the fluid introduced into the said vascular tree of the cell-free extracellular matrix. A method for cell removal from the tissue by perfusion is proposed, as well as a part of an organ with cells removed by perfusion.EFFECT: possibility of effective reconstruction of organ or tissue.16 cl, 2 dwg

eans for kidney fibrosis treatment // 2635460
FIELD: pharmacology.SUBSTANCE: invention relates to a carrier for delivering a substance to extracellular matrix producing cells in the kidney, the carrier consisting of a lipid structure containing a retinoid as a targeting agent, wherein the carrier has the form of a liposome. This invention also relates to a pharmaceutical composition for kidney fibrosis treatment, wherein the said carrier is used, to a method and a kit for its preparation.EFFECT: increased means application effeciency.8 cl, 3 ex, 2 dwg
ethod for silicone implant fixation and stabilization after skin-preserving mastectomy // 2635450
FIELD: medicine.SUBSTANCE: perforated sheet of acellular matrix is used and active drainage is installed. A silicone implant of the appropriate size and shape is installed in the prepared bed under the mobilized large pectoral muscle. A sheet of acellular matrix is pre-perforated by linear perforations in a staggered order, so that the sheet becomes a grid with a possibility of stretching in only one direction, sewed to the lower edge of the large pectoral muscle, aponeurosis of the rectus abdominis muscle in the projection of the submammary sulcus, and laterally - to the serratus anterior. The cellular tissue is sutured with separate sutures and skin is sutured with an intradermal suture.EFFECT: prevention of the silicone implant displacement, excluding the formation of pressure sores over the implant, palpable seals and unevenness under the breast skin, reduced likelihood of resistant seroma formation.1 ex, 10 dwg
ethod for body weight stabilisation // 2635190
FIELD: medicine.SUBSTANCE: method for body weight reduction by oral administration of an active ingredient, characterized by the active ingredient taken together with food products, carrot powder obtained by thermolabile drying at a temperature of not more than 40°C with simultaneous grinding of the raw material to obtain powder particles of less than 100 mcm in size is used as the active ingredient, oral administration is carried out 3 times a day with an active ingredient content of 2.5 to 3.5% by weight of the foodstuffs used.EFFECT: effective for body weight reduction with subsequent stabilisation of this weight.1 cl

Halides of 1-(4-tert-butylphenyl)-2-{3-[2-(4-fluoro-phenoxy)ethyl]-2-methyl-3h-benzimidazole-1-yl}ethanone with property of rupture cross-linkers of glycated proteins // 2635112
FIELD: chemistry.SUBSTANCE: halides of the formula 1 are described, possessing the property of rupture cross-linkers of glycated proteins.EFFECT: new halides that have beneficial biological properties.4 cl, 2 dwg, 1 tbl
ethod for enhancing level of work capacity of laboratory animals in experiment // 2634373
FIELD: medicine.SUBSTANCE: one hour before conducting Porsolt's tests and the vertical screen-grid animals are orally given a solution voluntarily using a pipette containing 4 g of creatine monohydrate and 5 g of honey per 100 ml of distilled water, at a dose of 5 ml per 1 kg of body weight.EFFECT: expansing the arsenal of means of actoprotective action while minimizing the pain and suffering of laboratory animals in experiment.2 tbl, 2 ex
ethod of transdermal delivery of biologically active substances // 2633928
FIELD: medicine.SUBSTANCE: for the transdermal delivery of biologically active substances (BAS), the application of containers with immobilized BAS to the surface of the skin is carried out, followed by transportation through the appendages of the skin. Porous calcium carbonate particles in a crystallographic modification of a vaterite with a size of less than 1,5 mcm are used as the containers. Transportation is carried out by exposing to ultrasound with an intensity of 0.1-1 W/cm2 with a duration of 1-4 minutes.EFFECT: effective filling of the hair follicles with particles while accelerating the procedure of introduction and providing the possibility to control the release duration of biologically active substances.4 cl, 2 tbl, 47 dwg, 15 ex

Pyridon derivatives // 2632885
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of formula (I) . New compounds and their crystalline forms that inhibit Ax1 and are useful for treatment of diseases caused by Ax1 hyperfunction, diseases associated with Ax1 hyperfunction, and/or diseases accompanied by Ax1 hyperfunction, such as hyperoproliferative disease.EFFECT: means have increased effectiveness.37 cl, 16 tbl, 107 ex, 16 dwg
ethod for biliary sludge treatment in patients with chronic biliar-dependent pancreatitis // 2632443
FIELD: medicine.SUBSTANCE: therapeutic diet ar per diet No. 5, per os odeston/hymecromone 400 mg 3 times a day, for 14 days are prescribed. From the 7th day of treatment, additional procedures of intensive pulsed magnetic field from the AMT2-"ATS" device are prescribed with "S" inductor location in the right hypochondrium area and "N" inductor - in the area of ThV-ThX segments, with the magnetic induction initial value of 100 mT and its subsequent increase by 100 mT in each subsequent procedure with a reduction to 800 mT, with pulse duration of 180 mcs in the "S" inductor, 110 mcs in the "N" inductor, number of pulses in the package - 2, number of packages - 25 per minute, with the duration of the first procedure of 6 minutes and the subsequent 2 minutes increase in each procedure, with a final session time of 18 minutes, daily, in 7 procedures.EFFECT: method increases the effectiveness of treatment by eliminating biliary sludge, improving bile colloidal properties.2 ex, 2 tbl

ethod for mammoplasty // 2631869
FIELD: medicine.SUBSTANCE: skin is cut along the areola. Penetration is performed through the incision into the retromammary space, a cavity for the implant is formed and drained. The implant is placed into the cavity, fibrin glue is injected into the cavity. The MG is brought to the given shape, fixed and sutured, the incision is glued. At that, 12-14 days prior to the operation, the MG surface is divided into squares with side length of ~ 2.0 cm and a mesh is applied. At the center of each square, botox is injected at a rate of 2.0-2.5 units per square. Also, botox is injected in the large pectoral muscle at a rate of 20-30 units per muscle. In addition, during the operation, prior to implant insertion into the cavity, botox injection is repeated at a rate of 20-30 units per muscle in the base and along the fibers of the large pectoral muscle. Fibrin glue is used in a mixture with a solution of a nonpolarizing muscle relaxant, and the cavity is washed with an antibiotic solution before drying.EFFECT: method has a high aesthetic effect, ensures the stability of the mammary gland with the necessary shape, excludes scars on the incision site, allows to significantly reduce postoperative rehabilitation and minimize or avoid postoperative pain sensations, local inflammatory processes and discomfort.3 cl, 19 dwg, 3 tbl, 3 ex
Compositions for treatment of fatigue related to cancer // 2631612
FIELD: pharmacology.SUBSTANCE: composition for cancer patients quality of life improvement is presented, containing water-ethanol extract of ginseng (Panax ginseng CA Mayer), lipophilic extract of zinziber (Zingiber officinale), lipophilic extract of narrow-leafed echinacea (Echinacea angustifolia) and a phospholipid complex of silybin with phospholipids selected from soybean lecithin and phosphatidylcholine as active ingredients taken in a certain amount, where the Panax ginseng CA Mayer extract is obtained from at least four-year-old roots; Zingiber officinale extract is obtained from roots and rhizomes, and Echinacea angustifolia extract has an isobutylamide content above 20 wt % in admixture with suitable excipients.EFFECT: composition is effective for cancer patients quality of life improvment.4 cl, 1 tbl, 2 ex
ethod for correction of violations in hemostasis system and microhemodynamics in case of peritonite in experiment // 2631610
FIELD: medicine.SUBSTANCE: for correction of disorders in the hemostatic system and microhemodynamics in case of peritonitis in an experiment, "Biorhythm-PC" phytococktail containing a mixture of 70% alcohol extracts of rhodiola rosea, licorice, spiny eleuterococcus, elfwort, taken at a ratio of 2:2:1:1 at a dosage of 0.05 ml per 100 grams of body weight per day is injected for 10 days prior to peritonitis modeling and 14 days after.EFFECT: method allows to increase the adaptive resources of the hemostasis system under stress conditions due to the restoration of regulatory interrelations in the pathological stress effect.1 tbl

Treatment of circadian rhythm violations // 2631602
FIELD: medicine.SUBSTANCE: for treatment of circadian rhythm violations, the patient suffering from "non-24" syndrome receives 20 mg of tazimelteone orally once in a day, before the required bedtime.EFFECT: biological clock adjustment to the 24-hour sleep-wake cycle.9 cl, 17 dwg, 10 tbl
ethod to increase frequency of embryo implantation in mammal mother uterus, application of effective amount of beta-galactoside-binding lectine or its derivatives, beta-galactosid-binding lectine or derivatives and product // 2631598
FIELD: medicine.SUBSTANCE: method is implemented by introduction of an effective amount of beta-galactoside-binding lectin or its alkylated form into the uterus of a mammal before the preimplantation period. The invention relates to application of an effective amount of beta-galactoside-binding lectin or its alkylated form to increase the frequency of embryo implantation in a mammal uterus by implementing the method, as well as to a product for increasing the frequency of embryo implantation in a healthy mammal uterus comprising an effective amount of beta-galactoside-binding lectin or its alkylated form.EFFECT: product application increases the number of embryonic implants in the uterus.17 cl, 2 tbl
Zinc acetate complex with 3-hydroxypyridine with anti-hypoxic activity under conditions of acute exogenous hypoxia // 2631496
FIELD: pharmacology.SUBSTANCE: invention relates to a zinc acetate complex with 3-hydroxypyridine of the formula: .EFFECT: metal complex has antihypoxic activity under conditions of acute exogenous hypoxia.1 tbl
ethod for lungs protection during cardiac surgery with artificial circulation // 2631105
FIELD: agriculture.SUBSTANCE: trachea intubation, artificial ventilation (AV) and ultra-hemofiltration are performed during artificial circulation. At the same time, after the beginning of AV and central vein catheterization, alprostadil is infused into it at a dose of 0.002-0.005 μg/kg/min during the entire operation until the patient is transferred to resuscitation. The pulmonary artery is perfused through an additional cannula mounted above the pulmonary artery valve. It is connected to an additional perfusion pump through an additional route with oxygenated blood, into which alprostadil is administered at a dose of 0.002-0.005 μg/kg/ min during the whole time of pulmonary artery perfusion, which is performed at a space velocity of 250-300 ml/min. During artificial circulation, ventilation is continued, reducing the respiratory volume to 50% of the initial, but not more than 5 ml/kg, reducing the respiratory rate to 5-6 times per minute.EFFECT: method allows to increase the effectiveness of lungs protection by preventing an increase in the alveolar-arterial oxygen gradient, to reduce the oxygenation and pulmonary compliance index, and to increase intrapulmonary shunting after artificial circulation.1 tbl, 1 ex
ethod for cow elementoses correction // 2630987
FIELD: veterinary medicine.SUBSTANCE: elemental composition of wool is determined by atomic emission and mass spectrometry, animals with a maximum permissible content of less than 94.9 mcg/kg for zinc, 0.201 mcg/g for selenium are detected, combined with excess concentrations of 0.038 mcg/kg for cadmium and 0.417 mcg /kg for lead. "Tagan-sorbent" in a dose 1 g per 1 kg of the animal's live weight is introduced to the identified animals' main diet for 30 days, at the end of which the animals are additionally injected with salts of trace elements equivalent to the introduction of zinc 0.26 g/head, selenium 0.02 g/head for 30 days.EFFECT: normalization of mineral metabolism in cows bodies.2 tbl
ethod for recovery of reserves and functional state of organism with application of phytoxicidal bath // 2630980
FIELD: medicine.SUBSTANCE: way of restoring reserves and functional condition of the organism in high-qualified athletes with the use of phytoxicidal baths, which consists in adding a phytoxicadal drug in the amount of 30-80 ml to the bath 300 l of water or 15-40 ml per 200 l of water and a bath appoint a course of 5-15 procedures once a day or every other day - in the evening, lasting 15-30 minutes at a temperature of 38-42°C. The agent contains an emulsion based on turpentine in an amount of from 50 to 95 wt % and phyto-supplements from 5 to 50 wt %, and the phyto-additive is a water-alkaline emulsion of the sum of the salts of triterpenic acids and neutral components obtained by treating the ground fir tree with a 0.5-5% aqueous solution of hydroxide or 1-5% aqueous solution of alkali metal carbonate in the ratio of raw materials: Extract - 1:5-12 with the subsequent simultaneous saponification of needle acids, emulsification of neutral components and filtration of the final product.EFFECT: method allows to adjust the functional state of the body and restore its reserves, improve the performance of athletes in training and competitive processes.2 tbl, 1 ex
Combination of traditional chinese medicine for immune function regulation and method for its production // 2630056
FIELD: pharmacology.SUBSTANCE: composition of traditional Chinese medicine for immunity regulation, which contains the following raw materials in parts by weight: 1-100 parts of Radix Panacis Quinquefolii, 1-100 parts of Ganoderma, 1-60 parts of Cordyceps sinensis fermented powder, 1-60 parts of Flos Rosae Rugosae and 1-60 parts of Rhizoma Anemarrhenae or one or more of their extracts. A composition of traditional Chinese medicine for immunity regulation. containing the following raw materials in parts by weight: (i) 1-100 parts of any of Radix Et Rhizoma Ginseng, Radix Codonopsis, Radix Pseudostellariae or Radix Astragali, or any of Radix Et Rhizoma Ginseng extract, Extract of Radix Codonopsis, extract of Radix Pseudostellariae or extract of Radix Astragali; (ii) 1-100 parts of Gandorema; (iii) 1-60 parts of Cordyceps or Cordyceps extract; (iv) 1-60 parts of Flos Rosae Rugosae and (v) 1-60 parts of Rhizoma Anemarrhenae. Method for obtaining of a composition of traditional Chinese medicine. Use of the composition in the manufacture of a medicament for allergic diseases prevention and treatment. Allergic diseases include allergic rhinitis, allergic asthma, atopic dermatitis and/or urticaria. Composition application in the manufacture of a medicament for viral diseases prevention and treatment. Viral diseases include hepatitis B and/or AIDS. Composition application for manufacture of a medicament that is effective in increasing of the leukocytes number. Composition application for manufacture of a medicament for radiation injury prevention and treatment. Composition application for manufacture of a medicament to reduce toxic and/or side effects resulting from radiation therapy and chemotherapy. Composition application for manufacture of a medicament for male sexual function improvement. Composition application for manufacture of a medicament for human body immunity enhancement. Composition application for production of a dietary food product or a medicament to alleviate physical fatigue.EFFECT: compositions described above are effective for immunity regulation.18 cl, 19 ex, 13 tbl
Pharmaceutical composition for homeostasis stabilization and pathological processes arresting in organism, and injection dosage form of this composition // 2629338
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition in the form of powder, the particles of which have a size of 1 nm to 150 nm, contains calcium, carbon, oxygen, potassium, sodium, magnesium, phosphorus, sulfur and chlorine in the amounts indicated in the claims. An injection dosage form of this composition is also described.EFFECT: pharmaceutical composition according to the invention provides replenishment of the microelements imbalance in the body and allows to accelerate the achievement of the therapeutic effect of arresting of pathological processes of various nature, including cancerous tumors.6 cl, 4 tbl, 5 ex
ethod for pressing the growth of mycobacterium tuberculosis polyresistent stamps in experiment // 2628624
FIELD: biotechnology.SUBSTANCE: in order to suppress the growth of multidrug resistant strains of Mycobacterium tuberculosis, a photodynamic effect is carried out in the experiment. As a photosensitizer, photoditazine at a concentration of 4⋅10-5 Mol/l. The irradiation is carried out with a low-intensity Azor-2K-02 laser with a wavelength of 660 nm, an output power of 25 mW emitting in a constant mode for 40 minutes at a power density of 0.32 mW/cm2 And an energy density of 0.76 J/cm2.EFFECT: method provides simple, reliable and effective inhibition of the growth of mycobacterium tuberculosis culture due to an additional inhibitory effect and enhancement of the bacteriostatic effect of laser irradiation of the cell culture treated with a photosensitizer.1 tbl

Dipeptidyl peptidase-4 inhibitor for treatment of type 2 diabetes // 2628573
FIELD: pharmacology.SUBSTANCE: application of (R/S)-3-amino-1-[(S)-5-phenyl-[1,2,4] oxadiazol-3-yl)-pyrrolidin-1-yl]-3-(4-fluorophenyl)-propan-1-one (with molecular mass Mr=380) in the form of hydrochloride (in terms of the salt form Mr=380+36.5 (HCl)=416.5), corresponding to the structural formula (I) as dipeptidyl peptidase-4 inhibitor for treatment of type 2 diabetes mellitus.EFFECT: chemical structure of the compound prevents its intramolecular cyclization, which preserves chemical and spatial structure in the natural conditions of the human body.4 dwg, 1 tbl, 6 ex

ethod for mammoplasty // 2628238
FIELD: medicine.SUBSTANCE: mammary gland (MG) plasty with high ptosis or a stretched "dermal sheath" is performed. At that, Botox is injected into the large pectoral muscle 8-10 days before the operation and into the cavity in the large pectoral muscle base during the operation, prior to implant insertion. During the operation, the MG skin within the operating field is shrunk by exposure to laser radiation or ultrasound. Fibrin glue mixed with a solution of a nonpolarizing muscle relaxant is used, and the cavity is washed with an antibiotic solution before drying.EFFECT: method has a high aesthetic effect, ensures the stability of the mammary gland with the necessary shape, minimizes ptosis, excludes scars on the incision site.3 cl, 14 dwg, 3 tbl, 3 ex

9-benzyl-2-biphenylimidazo[1,2-a]benzimidazole and pharmaceutically acceptable salts thereof that express properties of destroyers of transversal cross-links of glycosylated proteins // 2627769
FIELD: pharmacology.SUBSTANCE: invention relates to new 9-benzyl-2-biphenylimidazo[1,2-a]benzimidazole (I) and pharmaceutically acceptable salts thereof.EFFECT: imidazobenzimidazole derivatives having the property of destroyers of transversal cross-links of glycosylated proteins.3 cl, 2 dwg, 1 tbl, 1 ex
ethod for biofidobacterium metabolism products obtaining for treatment of combined radiation-thermal body damage and method for treatment of combined radiation-thermal body damage // 2627669
FIELD: medicine.SUBSTANCE: bifidobacteria are grown in 400-500 cm3 flasks with Blaurokk medium for 3-4 days in order to obtain products of their metabolism. The concentration of microbes is determined with standardization of their number to 1×108 CFU/cm. The bifidobacteria mixture with the products of their metabolism in the culture liquid is carefully shaken, poured into 50-100 cm3 centrifuge tube, centrifuged at 5000 rpm for 30 minutes. The resulting supernatant is decanted, the dry matter content is determined and adjusted to 10-15 mg/ml with physiological saline, sterilised by filtration, poured into bottles and stored in a refrigerator at a temperature of 4-6°C. Treatment of combined radiation-thermal body damage includes a 3-fold subcutaneous administration of the anti-ray serum of mammals mixed with metabolic products of bifidobacteria contained in the culture fluid obtained during the bifidobacteria growth in the ratio of 0.5:0.5 at a dose of 18.5-28 mg/kg in terms of protein, with an interval of 24, 48 and 168 hours after radiation-thermal trauma. Then, after 24, 48 and 168 hours, an ointment based on bee products and herbaceous oil is applied to the affected area.EFFECT: increased effectiveness of treatment of radiation-thermal body damage.2 cl, 4 tbl, 4 ex
Composition for physical stability and operability increase // 2626823
FIELD: pharmacology.SUBSTANCE: composition contains alpha-tocopherol acetate, retinol acetate, succinic acid and chocolate mass at the following ratio of the components, wt %: retinol acetate - 2.1-4.5; alpha-tocopherol acetate - 0.35-0.75; succinic acid 0.25-0.65; chocolate mass - the rest.EFFECT: composition according to the invention has good taste qualities, has a convenient form for administration, provides an increase in efficiency and physical endurance in a short time by taking a complex of active substances optimally selected and in an amount sufficient to achieve the maximum effect.2 tbl, 3 ex
Diet composition with treatment and preventive properties // 2626678
FIELD: pharmacology.SUBSTANCE: diet composition for intestinal microflora normalization is proposed, based on a mixture of prebiotics, including citric acid as monomeric substances, disaccharides as dimeric substances, inulin as polymer substances, natural gum; pectin, plant extracts and flavor. The composition contains stevia leaves extract, aqueous extracts of callisia fragrans shoots and white willow bark as plant extracts, the composition further contains glucosamine, and isomalt as disaccharide, with a certain ratio of components.EFFECT: composition described above increases the bioavailability of components, has a prebiotic, antioxidant, anti-inflammatory, immunomodulatory and restorative effect, effectively normalizes the intestinal microflora.1 tbl, 2 ex
Connections of substituted triazolbronic acid // 2625801
FIELD: chemistry.SUBSTANCE: invention relates to compounds of formula (I): , wherein the residues R1, R1' and R1ʺ independently represent hydrogen, alkoxy, halogen or -CF3 group. The residue R2 it represents C1-7alkyl or phenyl, or a pharmaceutically acceptable salt thereof. Also pharmaceutical composition, using the compounds of formula I, and method of treatment are provided.EFFECT: compounds of formula I are inhibitors immunoproteasomal subunit LMP7, and may be useful in the treatment of inflammatory diseases and disorders such as rheumatoid arthritis, lupus and irritable bowel syndrome.13 cl, 1 tbl, 5 ex
Application of rac-n-{4-[(2-ethoxy-3-octadecyloxy)propyl] oxycarbonylbutyl}-n-methyl-imidazoline iodide as a multikinase inhibitor // 2625749
FIELD: pharmacology.SUBSTANCE: application of rac-n-{4-[(2-ethoxy-3-octadecyloxy)propyl] oxycarbonylbutyl}-n-methyl-imidazoline iodide based on the identified activity as neoplastic cells Ins-R, MET, Src and Pim-1 protein kinases inhibitor.EFFECT: ability of the said compound to inhibit all the said protein kinases that mediate the carcinogenesis of those types of tumour cells in which they are actively expressed, unlike edelphosphine.1 tbl, 1 dwg, 2 ex
ethod of obtaining transfer factor for preventing viral bird diseases // 2624504
FIELD: veterinary medicine.SUBSTANCE: method of producing a transfer factor for the prevention of viral bid diseases, comprising preparing lymphocytes extract, hydrolysis by DNA, dialysis with subsequent preservation or lyophilization the title product, wherein the spleen of vaccinated against one or more infections, or recovered chickens or chickens is taken as a lymphocyte source.EFFECT: efficient preparation of the transfer factor from an extract of lymphocytes with increased yield.2 tbl, 2 ex
 
2551064.
Up!